

## **Australian Government**

## **Department of Health**

## Therapeutic Goods Administration

#### **Public Summary**

Summary for ARTG Entry: 297273 METAGENICS HPA ESSENTIALS

ARTG entry for Medicine Listed

Sponsor Metagenics (Aust) Pty Ltd

Postal Address PO Box 675, VIRGINIA BC, QLD, 4014

Australia

ARTG Start Date 7/12/2017

Product Category Medicine

Status Active

Approval Area Listed Medicines

#### Conditions

Colouring agents used in listed medicine for ingestion, other than those listed for export only under section 25 of the Act, shall be only those included in the list of 'Colourings permitted in medicines for oral use'.

The sponsor shall keep records relating to this listed medicine as are necessary to: (a) Expedite recall if necessary of any batch of the listed medicine, (b) Identify the manufacturer(s) of each batch of the listed medicine. Where any part of or step in manufacture in Australia of the listed medicine is sub-contracted to a third party who is not the sponsor, copies of relevant Good Manufacturing Practice agreements relation to such manufacture shall be kept.

The sponsor shall retain records of the distribution of the listed medicine for a period of five years and shall provide the records or copies of the records to the Complementary Medicines Branch, Therapeutic Goods Administration, upon request.

The sponsor of the listed medicine must not, by any means, intentionally or recklessly advertise the medicine for an indication other than those accepted in relation to the inclusion of the medicine in the Register.

All reports of adverse reactions or similar experiences associated with the use or administration of the listed medicine shall be notified to the Head, Office of Product Review, Therapeutic Goods Administration, as soon as practicable after the sponsor of the goods becomes aware of those reports. Sponsors of listed medicines must retain records of such reports for a period of not less than 18 months from the day the Head, Office of Product Review is notified of the report or reports.

The sponsor shall not supply the listed medicine after the expiry date of the goods.

Where a listed medicine is distributed overseas as well as in Australia, product recall or any other regulatory action taken in relation to the medicine outside Australia which has or may have relevance to the quality, safety or efficacy of the goods distributed in Australia, must be notified to the National Manager Therapeutic Goods Administration, immediately the action or information is known to the sponsor.

#### **Products**

## 1. METAGENICS HPA ESSENTIALS

Product Type Single Medicine Product Effective Date 30/01/2020

### **Permitted Indications**

Helps reduce/decrease free radical damage to body cells

Maintain/support energy levels

Maintain/support general health and wellbeing

Support healthy stress response in the body

Support healthy stress response in the body

Maintain/support neuroendocrine function

Aid/assist/helps synthesis of neurotransmitters

Maintain/support nervous system function

### Indication Requirements

Product presentation must not imply or refer to mental illnesses, disorders or conditions.

Product presentation must not imply or refer to chronic fatigue syndrome.

#### Standard Indications

No Standard Indications included on Record

## Specific Indications

No Specific Indications included on Record

#### Warnings

WARNING - Stop taking this medication if you experience tingling, burning or numbness and see your healthcare practitioner as soon as possible. [Contains vitamin B6].

#### Page 1 of 2

# Produced at 31.08.2021 at 06:09:00 AEST



# **Australian Government**

## **Department of Health**

## Therapeutic Goods Administration

If symptoms persist consult your healthcare practitioner (or words to that effect).

Vitamins and minerals can only be of assistance if dietary intake is inadequate OR Vitamin and/or mineral supplements should not replace a balanced diet.

#### **Additional Product information**

#### Pack Size/Poison information

Pack Size Poison Schedule

### Components

### 1 . Formulation 1

Dosage Form Tablet, film coated

Route of Administration Or

Visual Identification

#### **Active Ingredients**

**Biotin** 500 microgram calcium ascorbate dihydrate 545 mg Equivalent: ascorbic acid 450 mg calcium pantothenate 300 mg Citrus bioflavonoids extract 50 mg levomefolate calcium 217 microgram Equivalent: levomefolic acid 200 microgram mecobalamin (co-methylcobalamin) 200 microgram nicotinamide 50 mg pyridoxal 5-phosphate monohydrate 50 mg Equivalent: pyridoxine 32.5 mg riboflavin sodium phosphate 20 mg thiamine hydrochloride 50 mg

### Other Ingredients (Excipients)

calcium hydrogen phosphate dihydrate

chlorophyllin-copper complex

croscarmellose sodium

hypromellose

macrogol 400

magnesium stearate

maltodextrin

microcrystalline cellulose

silicon dioxide stearic acid

tartaric acid

© Commonwealth of Australia. This work is copyright. You are not permitted to re-transmit, distribute or commercialise the material without obtaining prior written approval from the Commonwealth. Further details can be found at http://www.tga.gov.au/about/website-copyright.htm.